| 产品名称 | ReVacc Scientific L1X97 | VSV-Pseudovirus_SARS-CoV-2 B.1.1.7 (Alpha strain) Spike with luciferase reporter |
|---|---|
| 目录号 | L1X97 |
| 别名 | VSV-Pseudovirus_SARS-CoV-2 B.1.1.7 (Alpha strain) Spike with luciferase reporter |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| L1X97 | 200 μl; 1000 μl | 咨询 | 咨询 |
ReVacc Scientific L1X97 | VSV-Pseudovirus_SARS-CoV-2 B.1.1.7 (Alpha strain) Spike with luciferase reporter
品名：VSV-Pseudovirus_SARS-CoV-2 B.1.1.7 (Alpha strain) Spike with luciferase reporter
货号：L1X97
品牌：ReVacc Scientific
规格：200 μl; 1000 μl
产品描述
Organism：SARS-Related Coronavirus 2 (virus caused COVID-19), B. 1.1.7 (Alpha strain) variant first identified in UK
This pseudotyped virus uses recombinant vesicular stomatitis virus (rVSV) to carry spike protein of SARS-CoV-2 (GenBank: MN908947) with multiple mutations initially identified in variant of B.1.1.7 (Alpha strain), including: ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. The spike protein has a 18-aa cytoplasmic tail truncation for optimal infection. As pseudovirus infectivity of rVSV without its original G is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See our titration result showing the undiluted pseudovirus (green) generates signal over 1,000-fold higher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of two control mAbs, including one published (Science, 2020: 369, p643) by using this pseudotyped virus, see results.
